NCT02362594 2026-03-05MK-3475-054Merck Sharp & Dohme LLCPhase 3 Active not recruiting1,019 enrolled 16 charts 1 FDA
NCT04099251 2025-08-27CheckMate76KBristol-Myers SquibbPhase 3 Active not recruiting790 enrolled 18 charts 1 FDA
NCT02908672 2025-07-20A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced MelanomaHoffmann-La RochePhase 3 Completed514 enrolled 25 charts 2 FDA
NCT03553836 2024-11-29KEYNOTE-716Merck Sharp & Dohme LLCPhase 3 Active not recruiting976 enrolled 15 charts 1 FDA